<DOC>
	<DOCNO>NCT01629381</DOCNO>
	<brief_summary>Study Objective : To assess value Rivaroxaban prevention venous thromboembolism ( VTE ) knee arthroscopy ( KA ) take placebo standard reference . Study Population : Patients undergo therapeutic KA study Centers , irrespective type duration procedure , eligible study . Study Design : Multicenter , randomize , double blind superiority , phase II trial compare two arm : - ( R-7d ) Rivaroxaban ( 10 mg od o ) 7 day - ( PL-7d ) Placebo 7 day . Follow-up : 3-month period randomization Standard Reference : Placebo standard reference accordance international guideline Study length May 2012-December 2012 Total patient number : 500 patient Primary Efficacy End-Point : Occurrence 3-month period randomization least one follow event , objectively prove ( mean CCDU ; multi-slice chest TC-angio ; autopsy , necessary , clinical ground ) : - All-cause mortality - Symptomatic VTE - Asymptomatic proximal DVT Secondary Efficacy End-point : â€¢ Combined incidence DVT plus symptomatic PE Primary Safety End-point : Incidence major bleeding . Secondary Safety End-point : Overall incidence bleeding</brief_summary>
	<brief_title>Efficacy RIvaroxaban Prevention Venous Thromboembolism After Knee Arthroscopy</brief_title>
	<detailed_description>The treatment administer postoperatively ( 1st dose 8-10 hour procedure ) , prevention venous thromboembolism KA . A bilateral whole-leg colour-coded Doppler ultrasonography ( CCDU ) schedule patient 7 ( +1 ) day follow-up ; additionally , CCDU due patient develop symptom sign suggestive venous thromboembolism earlier . Statistical &amp; Analytical Plan Methodology : In absence prophylaxis incidence venous thromboembolism ( primary efficacy end-point ) KA , assess CCDU , 8.0 % ( combine weight result various paper ) . Prophylaxis low-molecular weight heparin assure approximately 60-70 % relative risk reduction set . Based finding publish trial investigate efficacy Rivaroxaban prevention venous thromboembolism elective hip knee surgery , use low-molecular-weight heparin comparator , investigator speculate Rivaroxaban reduce incidence ( least 1.2 % ) .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>1 . Adult patient ( 18 year old ) 2 . Knee arthroscopy combine open surgery . 3 . Patients eligible surgical treatment . 4 . Patients willing able continue study participation ensure completion procedure observation require study . 5 . Written inform consent 1 . Diagnostic arthroscopy 2 . Patients concomitantly treat systemically strong concurrent CYP3A4 Pgpinhibitors , i.e . azoleantimycotics HIV protease inhibitor . 3 . Hypersensitivity active substance excipients study drug 4 . Pregnant woman breastfeed . 5 . Hepatic disease associate coagulopathy clinically relevant bleeding risk 6 . Known thrombophilia ( hereditary acquire ) 7 . Mandatory anticoagulation . 8 . Known severe bleeding tendency 9 . Clinically significant active bleeding . 10 . Severe renal failure ( GFR &lt; 30mL/min/1.73m2 ) 11 . Patients participate another clinical trial . 12 . Recent mayor surgery ( 6 12 week )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>knee arthroscopy</keyword>
	<keyword>venous thromboembolism</keyword>
	<keyword>prevention</keyword>
</DOC>